Thomas L. Schwartz

4.1k total citations
79 papers, 2.3k citations indexed

About

Thomas L. Schwartz is a scholar working on Pharmacology, Psychiatry and Mental health and Experimental and Cognitive Psychology. According to data from OpenAlex, Thomas L. Schwartz has authored 79 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pharmacology, 36 papers in Psychiatry and Mental health and 13 papers in Experimental and Cognitive Psychology. Recurrent topics in Thomas L. Schwartz's work include Treatment of Major Depression (27 papers), Schizophrenia research and treatment (25 papers) and Bipolar Disorder and Treatment (11 papers). Thomas L. Schwartz is often cited by papers focused on Treatment of Major Depression (27 papers), Schizophrenia research and treatment (25 papers) and Bipolar Disorder and Treatment (11 papers). Thomas L. Schwartz collaborates with scholars based in United States, United Kingdom and Norway. Thomas L. Schwartz's co-authors include Prakash S. Masand, Nikhil Nihalani, Stephen M. Stahl, Shilpa Sachdeva, Subhdeep Virk, Sahil Jindal, Taeyoung Park, Natasha Jones, Frederick W. Reimherr and Mark Bunker and has published in prestigious journals such as SHILAP Revista de lepidopterología, American Journal of Psychiatry and Biological Psychiatry.

In The Last Decade

Thomas L. Schwartz

74 papers receiving 2.2k citations

Peers

Thomas L. Schwartz

PMH

PHARM

NEURO

CMN

J.C. Ballenger United States

Paul J. Goodnick United States

Chih‐Sung Liang Taiwan

Te‐Jen Lai Taiwan

Dominika Dudek Poland

K. Ranga R. Krishnan United States

Jakub Z. Konarski Canada

Peter Bentham United Kingdom

Tommi Tolmunen Finland

Marcin Siwek Poland

J.C. Ballenger United States

Thomas L. Schwartz

555 ×0.8

PMH

426 ×0.9

PHARM

328 ×0.9

234 ×0.7

NEURO

190 ×0.7

CMN

Citations per year, relative to Thomas L. Schwartz Thomas L. Schwartz (= 1×) peers J.C. Ballenger

Countries citing papers authored by Thomas L. Schwartz

Since Specialization

Citations

This map shows the geographic impact of Thomas L. Schwartz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas L. Schwartz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas L. Schwartz more than expected).

Fields of papers citing papers by Thomas L. Schwartz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas L. Schwartz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas L. Schwartz. The network helps show where Thomas L. Schwartz may publish in the future.

Co-authorship network of co-authors of Thomas L. Schwartz

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas L. Schwartz. A scholar is included among the top collaborators of Thomas L. Schwartz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas L. Schwartz. Thomas L. Schwartz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schwartz, Thomas L., et al.. (2016). Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Therapeutic Advances in Psychopharmacology. 7(1). 29–41. 90 indexed citations

Schwartz, Thomas L., et al.. (2016). How to Control Weight Gain When Prescribing Antidepressants: Address Diet and Exercise First, Then Consider Switching Antidepressants or Prescribing an Adjunctive Agent. Current psychiatry. 15(6). 30. 1 indexed citations

Schwartz, Thomas L., et al.. (2015). Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs in Context. 4. 1–12. 145 indexed citations

Schwartz, Thomas L., et al.. (2015). Tramadol for the treatment of fibromyalgia. Expert Review of Neurotherapeutics. 15(5). 469–475. 12 indexed citations

Aaronson, Scott T., Linda L. Carpenter, Charles R. Conway, et al.. (2012). Vagus Nerve Stimulation Therapy Randomized to Different Amounts of Electrical Charge for Treatment-Resistant Depression: Acute and Chronic Effects. Brain stimulation. 6(4). 631–640. 126 indexed citations

Schwartz, Thomas L. & Mandeep Singh. (2012). Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use. Neuropsychiatric Disease and Treatment. 8. 123–123. 16 indexed citations

Schwartz, Thomas L. & Stephen M. Stahl. (2011). Treatment Strategies for Dosing the Second Generation Antipsychotics. CNS Neuroscience & Therapeutics. 17(2). 110–117. 27 indexed citations

Schwartz, Thomas L., Zsuzsa Szombathyne Meszaros, Rahat Khan, & Nikhil Nihalani. (2007). How to Control Weight Gain When Prescribing Antidepressants: Ignoring This Side Effect Can Increase Medical Risk, Treatment Nonadherence. Current psychiatry. 6(5). 43. 4 indexed citations

Nihalani, Nikhil & Thomas L. Schwartz. (2007). Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression.. PubMed. 8(7). 563–9. 20 indexed citations

10.

Schwartz, Thomas L., et al.. (2007). Modafinil Treatment for Fatigue Associated with Fibromyalgia. JCR Journal of Clinical Rheumatology. 13(1). 52–52. 16 indexed citations

11.

Schwartz, Thomas L., et al.. (2007). An Open-Label Study to Evaluate Switching from an SSRI or SNRI to Tiagabine to Alleviate Antidepressant-Induced Sexual Dysfunction in Generalized Anxiety Disorder. Annals of Clinical Psychiatry. 19(1). 25–30. 6 indexed citations

12.

Schwartz, Thomas L., et al.. (2006). The use of ramelteon for secondary insomnia due to mental illness. 13(12). 69–73.

13.

Schwartz, Thomas L., et al.. (2005). Antidepressant Treatment in the Primary Care Office: Outcomes for Adjustment Disorder Versus Major Depression. Annals of Clinical Psychiatry. 17(2). 77–81. 26 indexed citations

14.

Virk, Subhdeep, Thomas L. Schwartz, Sahil Jindal, Nikhil Nihalani, & Natasha Jones. (2004). Psychiatric medication induced obesity: an aetiologic review. Obesity Reviews. 5(3). 167–170. 50 indexed citations

15.

Schwartz, Thomas L., Nikhil Nihalani, Subhdeep Virk, Sahil Jindal, & Mark Chilton. (2004). Psychiatric medication‐induced obesity: treatment options. Obesity Reviews. 5(4). 233–238. 38 indexed citations

16.

Schwartz, Thomas L., et al.. (2004). An Open-Label Study of Adjunctive Modafinil in Patients With Sedation Related to Serotonergic Antidepressant Therapy. The Journal of Clinical Psychiatry. 65(9). 1223–1227. 27 indexed citations

17.

Masand, Prakash S., Xiaohong Wang, Sanjay Gupta, et al.. (2002). Comparison of Risperidone and Olanzapine in Bipolar and Schizoaffective Disorders. The Primary Care Companion For CNS Disorders. 4(2). 70–73. 8 indexed citations

18.

Masand, Prakash S., Sanjay Gupta, Thomas L. Schwartz, et al.. (2002). Paroxetine in Patients With Irritable Bowel Syndrome. The Primary Care Companion For CNS Disorders. 4(1). 12–16. 25 indexed citations

19.

Schwartz, Thomas L. & Prakash S. Masand. (2000). Treatment of Delirium With Quetiapine. The Primary Care Companion For CNS Disorders. 2(1). 10–12. 61 indexed citations

20.

Schwartz, Thomas L. & Taeyoung Park. (1999). Assaults by Patients on Psychiatric Residents: A Survey and Training Recommendations. Psychiatric Services. 50(3). 381–383. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact